DE60142228D1 - Zusammensetzungen und methoden zur identifizierung und zum targeting von krebszellen aus dem verdauungskanal - Google Patents
Zusammensetzungen und methoden zur identifizierung und zum targeting von krebszellen aus dem verdauungskanalInfo
- Publication number
- DE60142228D1 DE60142228D1 DE60142228T DE60142228T DE60142228D1 DE 60142228 D1 DE60142228 D1 DE 60142228D1 DE 60142228 T DE60142228 T DE 60142228T DE 60142228 T DE60142228 T DE 60142228T DE 60142228 D1 DE60142228 D1 DE 60142228D1
- Authority
- DE
- Germany
- Prior art keywords
- methods
- compositions
- identifying
- cancer cells
- targeting cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000001079 digestive effect Effects 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 3
- 201000004101 esophageal cancer Diseases 0.000 abstract 3
- 230000001394 metastastic effect Effects 0.000 abstract 3
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 3
- 210000002784 stomach Anatomy 0.000 abstract 3
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 2
- 206010017758 gastric cancer Diseases 0.000 abstract 2
- 201000011549 stomach cancer Diseases 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19222900P | 2000-03-27 | 2000-03-27 | |
PCT/US2001/009790 WO2001073132A1 (en) | 2000-03-27 | 2001-03-27 | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60142228D1 true DE60142228D1 (de) | 2010-07-08 |
Family
ID=22708782
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60140865T Expired - Lifetime DE60140865D1 (de) | 2000-03-27 | 2001-03-27 | Zusammensetzungen und methoden zur identifizierung von krebszellen |
DE60142228T Expired - Lifetime DE60142228D1 (de) | 2000-03-27 | 2001-03-27 | Zusammensetzungen und methoden zur identifizierung und zum targeting von krebszellen aus dem verdauungskanal |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60140865T Expired - Lifetime DE60140865D1 (de) | 2000-03-27 | 2001-03-27 | Zusammensetzungen und methoden zur identifizierung von krebszellen |
Country Status (10)
Country | Link |
---|---|
US (20) | US20010036635A1 (de) |
EP (6) | EP3388534A1 (de) |
JP (3) | JP5122713B2 (de) |
AT (2) | ATE452989T1 (de) |
AU (3) | AU2001249503A1 (de) |
CA (3) | CA2404428A1 (de) |
DE (2) | DE60140865D1 (de) |
ES (2) | ES2346637T3 (de) |
PT (1) | PT1272665E (de) |
WO (3) | WO2001073131A1 (de) |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7097839B1 (en) * | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5879656A (en) * | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
US6692952B1 (en) * | 1999-11-10 | 2004-02-17 | Massachusetts Institute Of Technology | Cell analysis and sorting apparatus for manipulation of cells |
DE60140865D1 (de) * | 2000-03-27 | 2010-02-04 | Univ Jefferson | Zusammensetzungen und methoden zur identifizierung von krebszellen |
WO2002022885A1 (en) * | 2000-09-18 | 2002-03-21 | Thomas Jefferson University | Compositions and methods for identifying and targeting stomach and esophageal cancer cells |
WO2002074979A2 (en) * | 2001-03-20 | 2002-09-26 | Ortho-Clinical Diagnostics, Inc. | Expression profiles and methods of use |
ES2375724T3 (es) * | 2002-09-27 | 2012-03-05 | The General Hospital Corporation | Dispositivo microflu�?dico para seperación de células y sus usos. |
WO2004044178A2 (en) * | 2002-11-13 | 2004-05-27 | Genentech, Inc. | Methods and compositions for diagnosing dysplasia |
DE10259703A1 (de) * | 2002-12-19 | 2004-07-08 | Ivonex Gmbh | Trennungsverfahren |
US7422865B2 (en) * | 2003-01-13 | 2008-09-09 | Agilent Technologies, Inc. | Method of identifying peptides in a proteomic sample |
US8206704B2 (en) | 2003-02-10 | 2012-06-26 | Thomas Jefferson University | Use of GCC ligands |
WO2004077021A2 (en) * | 2003-02-27 | 2004-09-10 | Lesko Stephen A | Standardized evaluation of therapeutic efficacy based on cellular biomarkers |
US10533998B2 (en) | 2008-07-18 | 2020-01-14 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
US20070160503A1 (en) * | 2003-06-13 | 2007-07-12 | Palaniappan Sethu | Microfluidic systems for size based removal of red blood cells and platelets from blood |
CA2526284C (en) | 2003-06-25 | 2014-11-18 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
DE602004024539D1 (de) * | 2003-07-03 | 2010-01-21 | Gentron Llc | Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben |
EP1670511B1 (de) * | 2003-09-15 | 2009-07-29 | Research Development Foundation | Cripto-antagonismus von activin und tgf-b signalisierung |
WO2005040163A1 (en) * | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd | Heterocyclic compounds that block the effects of advanced glycation end products (age) |
AU2004289539C1 (en) | 2003-11-14 | 2012-06-07 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
AU2005218622A1 (en) * | 2004-03-03 | 2005-09-15 | Living Microsystems | Magnetic device for isolation of cells and biomolecules in a microfluidic environment |
US20050221339A1 (en) * | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
EP1781339B1 (de) | 2004-06-25 | 2013-12-25 | Thomas Jefferson University | Guanylylcyclase C Liganden |
EP2272987A3 (de) * | 2004-07-09 | 2012-04-11 | University of Pittsburgh of the Commonwealth System of Higher Education | Identifizierung von Markern für Speiseröhren-, Dickdarm-, Kopf- und Nackenkrebs und Melanom |
US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
US8535914B2 (en) * | 2005-01-21 | 2013-09-17 | Canon Kabushiki Kaisha | Probe, probe set and information acquisition method using the same |
US20070026415A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026417A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026414A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070196820A1 (en) * | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
US20070026413A1 (en) * | 2005-07-29 | 2007-02-01 | Mehmet Toner | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US8921102B2 (en) * | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070059680A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for cell enrichment |
US20070026416A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20090181421A1 (en) * | 2005-07-29 | 2009-07-16 | Ravi Kapur | Diagnosis of fetal abnormalities using nucleated red blood cells |
US7939649B2 (en) * | 2005-09-06 | 2011-05-10 | Stanford University | Polynucleotide encoding luciferase |
US20070059781A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for size based separation and analysis |
US20070059774A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Kits for Prenatal Testing |
US20070059683A1 (en) * | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
AU2006330947B2 (en) | 2005-12-22 | 2012-04-12 | Pacific Biosciences Of California, Inc. | Polymerases for nucleotide analogue incorporation |
AU2006331677A1 (en) * | 2005-12-22 | 2007-07-05 | Pacific Biosciences Of California, Inc. | Protein engineering strategies to optimize activity of surface attached proteins |
CA2633476C (en) * | 2005-12-22 | 2015-04-21 | Pacific Biosciences Of California, Inc. | Active surface coupled polymerases |
WO2007081386A2 (en) | 2006-01-11 | 2007-07-19 | Raindance Technologies, Inc. | Microfluidic devices and methods of use |
JP2007215412A (ja) * | 2006-02-14 | 2007-08-30 | Shizuoka Prefecture | 悪性転移性胃癌の判定方法 |
US20070207467A1 (en) * | 2006-03-01 | 2007-09-06 | Ming Xu | Detection of lymph node metastasis from gastric carcinoma |
US20080014589A1 (en) | 2006-05-11 | 2008-01-17 | Link Darren R | Microfluidic devices and methods of use thereof |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
BRPI0713098A2 (pt) * | 2006-05-22 | 2012-10-16 | Clinical Genomics Pty Ltd | método para determinar a origem anatÈmica de uma célula ou população celular derivada do intestino grosso de um indivìduo, método de detecção para determinar a origem anatÈmica de uma célula ou população celular derivada do intestino grosso de um indivìduo, sistema de detecção, meio de armazenagem legìvel por computador, arranjo de ácido nucleico, uso de um arranjo, método para determinar o inìcio ou predisposição para o inìcio de uma anormalidade celular ou uma condição destinguida por uma anormalidade celular no intestino grosso, kit de diagnóstico para ensaiar amostras biológicas |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US20080070792A1 (en) | 2006-06-14 | 2008-03-20 | Roland Stoughton | Use of highly parallel snp genotyping for fetal diagnosis |
US20080050739A1 (en) * | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
EP2589668A1 (de) | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Analyse seltener Zellen mittels Probentrennung und DNA-Etiketten |
EP2077912B1 (de) | 2006-08-07 | 2019-03-27 | The President and Fellows of Harvard College | Fluorkohlenstoffemulsionsstabilisierende tenside |
ATE522813T1 (de) * | 2006-09-07 | 2011-09-15 | Universitaetsklinikum Hamburg | Verfahren für den nachweis karzinomatöser epithelzellen mittels freigesetzter zytokeratine als marker für diese zellen |
WO2008051530A2 (en) * | 2006-10-23 | 2008-05-02 | Pacific Biosciences Of California, Inc. | Polymerase enzymes and reagents for enhanced nucleic acid sequencing |
US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US8679759B2 (en) * | 2007-08-01 | 2014-03-25 | The Johns Hopkins University | Esophageal cancer markers |
CA2706442C (en) * | 2007-11-27 | 2017-07-11 | Veridex, Llc | Automated enumeration and characterization of circulating melanoma cells in blood |
US20110195415A1 (en) * | 2008-05-13 | 2011-08-11 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
WO2010009365A1 (en) | 2008-07-18 | 2010-01-21 | Raindance Technologies, Inc. | Droplet libraries |
SI2334812T1 (sl) | 2008-09-20 | 2017-05-31 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel Building 170 | Neinvazivna diagnoza fetalne anevploidije s sekvenciranjem |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
WO2010096929A1 (en) | 2009-02-25 | 2010-09-02 | Diagnocure Inc. | Method for detecting metastasis of gi cancer |
US8528589B2 (en) | 2009-03-23 | 2013-09-10 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
EP2486409A1 (de) | 2009-10-09 | 2012-08-15 | Universite De Strasbourg | Markiertes nanomaterial auf siliziumbasis mit verbesserten eigenschaften und seine verwendung |
EP2491116A4 (de) | 2009-10-22 | 2013-12-11 | Univ Jefferson | Zellbasierte antikrebszusammensetzungen sowie verfahren zu ihrer herstellung und verwendung |
IN2012DN02604A (de) * | 2009-10-23 | 2015-09-04 | Millennium Pharm Inc | |
CA2778639A1 (en) * | 2009-11-05 | 2011-05-12 | Sequent Medical Inc. | Multiple layer filamentary devices or treatment of vascular defects |
GB0920014D0 (en) * | 2009-11-13 | 2009-12-30 | Medical Res Council | Cell sampling device |
US8187979B2 (en) * | 2009-12-23 | 2012-05-29 | Varian Semiconductor Equipment Associates, Inc. | Workpiece patterning with plasma sheath modulation |
US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
US9217032B2 (en) * | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
WO2011100604A2 (en) | 2010-02-12 | 2011-08-18 | Raindance Technologies, Inc. | Digital analyte analysis |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
PL2550294T3 (pl) | 2010-03-24 | 2020-03-31 | Progastrine Et Cancers S.À R.L. | Profilaktyka nowotworu jelita grubego i nowotworu przewodu pokarmowego |
US8932866B2 (en) | 2010-04-06 | 2015-01-13 | Kagoshima University | Method for inspecting gastroenterological cancer by utilizing N-linked sugar chain |
EP3447155A1 (de) | 2010-09-30 | 2019-02-27 | Raindance Technologies, Inc. | Sandwichassays in tröpfchen |
WO2012109600A2 (en) | 2011-02-11 | 2012-08-16 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
WO2012112804A1 (en) | 2011-02-18 | 2012-08-23 | Raindance Technoligies, Inc. | Compositions and methods for molecular labeling |
EP2686688B1 (de) | 2011-03-17 | 2019-05-08 | Cernostics, Inc. | Systeme und zusammensetzungen zur diagnose von barrett-ösophagen und verwendungsverfahren dafür |
CN102311458A (zh) * | 2011-05-31 | 2012-01-11 | 江苏省原子医学研究所 | 一种99mTcO核标记的苯丁酸氮芥类配合物、其制备分离纯化方法及其用途 |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
US20140363825A1 (en) * | 2011-08-29 | 2014-12-11 | Kyoto University | Marker for detecting colorectal cancer or esophageal cancer and method for examining such cancer |
JP2013083490A (ja) | 2011-10-06 | 2013-05-09 | Kagoshima Univ | 消化器癌診断用マーカー、および消化器癌の検査方法 |
WO2013120089A1 (en) | 2012-02-10 | 2013-08-15 | Raindance Technologies, Inc. | Molecular diagnostic screening assay |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
PE20142322A1 (es) | 2012-04-27 | 2015-01-25 | Millennium Pharm Inc | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc |
WO2013165748A1 (en) | 2012-04-30 | 2013-11-07 | Raindance Technologies, Inc | Digital analyte analysis |
JP6352909B2 (ja) | 2012-06-27 | 2018-07-04 | バーグ エルエルシー | 前立腺癌の診断および処置におけるマーカーの使用 |
US9396532B2 (en) * | 2012-11-15 | 2016-07-19 | Siemens Healthcare Diagnostics, Inc. | Cell feature-based automatic circulating tumor cell detection |
CN105142664A (zh) * | 2013-02-28 | 2015-12-09 | 米伦纽姆医药公司 | 投予抗gcc抗体-药物结合物和dna破坏剂来治疗癌症 |
EP2986762B1 (de) | 2013-04-19 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Digitale analyse von analyten |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
DK3052102T3 (da) | 2013-10-04 | 2020-03-09 | Aptose Biosciences Inc | Sammensætninger til behandling af cancere |
US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
EP3090063B1 (de) | 2013-12-31 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Verfahren zur detektion von latentem retrovirus |
US20170067912A1 (en) * | 2014-03-13 | 2017-03-09 | The Penn State Research Foundation | Compositions and methods for diagnosing barrett's esophagus stages |
CA2970143A1 (en) | 2014-12-08 | 2016-06-16 | Berg Llc | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
KR20180026659A (ko) | 2015-03-18 | 2018-03-13 | 더 존스 홉킨스 유니버시티 | 포타슘 채널 kcnk9를 표적화하는 신규한 모노클로날 항체 억제제 |
CN108135875B (zh) | 2015-07-31 | 2021-12-31 | 约翰霍普金斯大学 | 用于治疗代谢重编程病症的方法和组合物 |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
EP3786640B1 (de) | 2015-11-25 | 2022-08-24 | Cernostics, Inc. | Verfahren zum nachweis maligner transformation von barrett-esophagus |
GB201604806D0 (en) * | 2016-03-22 | 2016-05-04 | Singapore Volition Pte Ltd | Method of identifying a cancer of unknown origin |
CN106124764B (zh) * | 2016-08-12 | 2018-03-09 | 上海市嘉定区中心医院 | 以hoxb9和pbx1作为生物标志物的胃癌检测试剂盒及应用 |
KR101966642B1 (ko) | 2017-03-14 | 2019-04-09 | (주) 노보믹스 | 진행성 위암 환자의 수술 후 예후 또는 항암제 적합성 예측 시스템 |
KR20200108409A (ko) * | 2017-08-18 | 2020-09-18 | 토마스 제퍼슨 유니버시티 | 암 치료에서의 정상 조직의 보호 |
US10998178B2 (en) | 2017-08-28 | 2021-05-04 | Purdue Research Foundation | Systems and methods for sample analysis using swabs |
US11773449B2 (en) | 2017-09-01 | 2023-10-03 | The Hospital For Sick Children | Profiling and treatment of hypermutant cancer |
KR20200096914A (ko) | 2017-10-30 | 2020-08-14 | 압토스 바이오사이언시스 인코포레이티드 | 암 치료용 아릴 이미다졸 |
FI128634B (en) * | 2019-06-07 | 2020-09-15 | Nokia Solutions & Networks Oy | Obtaining information |
TW202237639A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3130883A (en) * | 1962-03-01 | 1964-04-28 | Lewis J Mackool | Hatchet scabbard |
US4375414A (en) | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
US4022878A (en) | 1972-05-15 | 1977-05-10 | Biological Developments, Inc. | Methods and compounds for producing specific antibodies |
US4526716A (en) | 1981-11-20 | 1985-07-02 | The Ohio State University | Antigenic modification of polypeptides |
US4329281A (en) | 1978-06-05 | 1982-05-11 | Hoffmann-La Roche Inc. | Hapten compositions |
US4264024A (en) * | 1978-12-21 | 1981-04-28 | Harris Jr Ellsworth L | Smoking pipe sling |
US4341763A (en) | 1981-03-10 | 1982-07-27 | Smithkline-Rit | Methods of vaccinating humans against rotavirus infection |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4584268A (en) | 1981-10-13 | 1986-04-22 | Ceriani Roberto Luis | Method and compositions for carcinoma diagnosis |
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
GB8328918D0 (en) | 1983-10-28 | 1983-11-30 | Unilever Plc | Alkaline phosphatase |
ZA839512B (en) | 1983-12-12 | 1984-08-29 | Scripps Clinic Res | Synthetic heat-stable enterotoxin polypeptide of escherichia coli and multimers thereof |
US4601896A (en) | 1984-03-21 | 1986-07-22 | Mark Nugent | Pharmaceutical capsule compositions and structures for gastric sensitive materials |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4729893A (en) | 1984-12-26 | 1988-03-08 | Robert L. Letcher | Enteric encapsulation of ancrod for oral administration |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US5160723A (en) | 1985-04-19 | 1992-11-03 | Sloan-Kettering Institute For Cancer Research | Method of imaging colorectal carcinoma lesion and composition for use therein |
GB8519457D0 (en) | 1985-08-02 | 1985-09-11 | Faulk Ward Page | Tumour imaging agents |
JPS62162963A (ja) | 1986-01-10 | 1987-07-18 | Sadao Shiosaka | 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法 |
US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
IN165717B (de) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US5399347A (en) | 1987-06-24 | 1995-03-21 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
US5217869A (en) | 1987-10-13 | 1993-06-08 | Terrapin Technologies, Inc. | Method to produce immunodiagnostic reagents |
US4963263A (en) | 1988-03-24 | 1990-10-16 | Terrapin Technologies, Inc. | Method of identity analyte-binding peptides |
US5133866A (en) | 1988-03-24 | 1992-07-28 | Terrapin Technologies, Inc. | Method to identify analyte-bending ligands |
US5340474A (en) | 1988-03-24 | 1994-08-23 | Terrapin Technologies, Inc. | Panels of analyte-binding ligands |
US5350741A (en) | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
US4923949A (en) | 1988-08-03 | 1990-05-08 | Kanegafuchi Chemical Industry Co., Ltd. | Ethynylene-disilanylene copolymers and method of preparing same |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
US5049656A (en) | 1988-12-21 | 1991-09-17 | Board Of Regents Of The University Of Nebraska | Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques |
ES2200016T3 (es) | 1989-03-21 | 2004-03-01 | Vical Incorporated | Expresion de secuencias polinucleotidicas exogenas en un vertebrado. |
US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5443816A (en) | 1990-08-08 | 1995-08-22 | Rhomed Incorporated | Peptide-metal ion pharmaceutical preparation and method |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5252743A (en) | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
US5366862A (en) | 1990-02-14 | 1994-11-22 | Receptor Laboratories, Inc. | Method for generating and screening useful peptides |
CA2039517C (en) * | 1990-04-03 | 2006-11-07 | David Segev | Dna probe signal amplification |
US5430138A (en) | 1990-07-27 | 1995-07-04 | Chiron Corporation | Hydroxyl-protecting groups attached to cytidine nucleotide compounds which are orthogonally removable |
US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
US5352775A (en) | 1991-01-16 | 1994-10-04 | The Johns Hopkins Univ. | APC gene and nucleic acid probes derived therefrom |
KR930702985A (ko) | 1991-02-21 | 1993-11-29 | 스튜어트 알.슈터 | 식도암의 치료 |
US5330892A (en) | 1991-03-13 | 1994-07-19 | The Johns Hopkins University | MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans |
AU662906B2 (en) | 1991-06-26 | 1995-09-21 | F. Hoffmann-La Roche Ag | Methods for detection of carcinoma metastases by nucleic acid amplification |
US5140102A (en) * | 1991-09-23 | 1992-08-18 | Monsanto Company | Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
US5395750A (en) | 1992-02-28 | 1995-03-07 | Hoffmann-La Roche Inc. | Methods for producing proteins which bind to predetermined antigens |
US5969097A (en) * | 1992-06-23 | 1999-10-19 | G. D. Searle & Co. | Human guanylin |
US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
US5420328A (en) | 1992-09-11 | 1995-05-30 | Affymax Technologies, N.V. | Methods for the synthesis of phosphonate esters |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5324483B1 (en) | 1992-10-08 | 1996-09-24 | Warner Lambert Co | Apparatus for multiple simultaneous synthesis |
US5397639A (en) | 1992-11-25 | 1995-03-14 | Tollini; Dennis R. | Securing tape |
US5595739A (en) | 1993-05-07 | 1997-01-21 | Abbott Laboratories | Hepatitis B virus mutants, reagents and methods for detection |
US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5601990A (en) * | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
CA2174928C (en) | 1993-10-26 | 2011-08-16 | Scott A. Waldman | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
US7097839B1 (en) * | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5962220A (en) | 1993-10-26 | 1999-10-05 | Thomas Jefferson University | Compositions that specifically bind to colorectal cells and methods of using the same |
US5489670A (en) * | 1993-10-29 | 1996-02-06 | G. D. Searle & Co. | Human uroguanylin |
US5885574A (en) * | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
US5597909A (en) * | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5858011A (en) | 1995-08-02 | 1999-01-12 | The Procter & Gamble Company | Disposable absorbent article having a resilient member |
EP0891550A1 (de) * | 1996-04-05 | 1999-01-20 | The Johns Hopkins University School Of Medicine | Verfahren zur anreicherung von seltenen zellen |
CA2224970C (en) * | 1996-04-16 | 2002-04-02 | Kishimoto, Tadamitsu | Method of detecting solid cancer cells and tissue atypia and method of testing tissues for use in bone marrow transplantation and peripheral blood stem cell transplantation |
WO1997042506A1 (en) | 1996-05-03 | 1997-11-13 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
DE69723580T2 (de) | 1996-05-03 | 2004-06-03 | Thomas Jefferson University | Impfstoff gegen metastasierenden kolorektalkrebs. |
US5914238A (en) * | 1996-06-05 | 1999-06-22 | Matritech, Inc. | Materials and methods for detection of breast cancer |
AU4003597A (en) * | 1996-09-04 | 1998-03-26 | Howard Florey Institute Of Experimental Physiology And Medicine | Methods of diagnosing and treating cancer |
FI971124A0 (fi) * | 1997-03-18 | 1997-03-18 | Locus Genex Oy | Metod foer diagnostisering av magcancer |
US5874266A (en) * | 1997-03-27 | 1999-02-23 | Palsson; Bernhard O. | Targeted system for removing tumor cells from cell populations |
WO1998050567A1 (en) * | 1997-05-02 | 1998-11-12 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
US6120995A (en) * | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
JP2002526760A (ja) * | 1998-10-02 | 2002-08-20 | ダイアデクスアス・インコーポレーテッド | 消化器癌を診断、監視、病期分類、イメージング及び治療する新規な方法 |
WO2000047998A1 (en) * | 1999-02-10 | 2000-08-17 | Cell Works Inc. | Class characterization of circulating cancer cells isolated from body fluids and methods of use |
EP2325321A1 (de) * | 1999-05-28 | 2011-05-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vacciniavirus-Vektor, in dem sowohl Wachstumsfaktor als auch Thymidinkinase deletiert sind |
DE60140865D1 (de) * | 2000-03-27 | 2010-02-04 | Univ Jefferson | Zusammensetzungen und methoden zur identifizierung von krebszellen |
WO2002022885A1 (en) * | 2000-09-18 | 2002-03-21 | Thomas Jefferson University | Compositions and methods for identifying and targeting stomach and esophageal cancer cells |
US6652378B2 (en) | 2001-06-01 | 2003-11-25 | Igt | Gaming machines and systems offering simultaneous play of multiple games and methods of gaming |
US20050257067A1 (en) * | 2002-08-30 | 2005-11-17 | Roberts David K | Fingerprint embedding |
US8206704B2 (en) * | 2003-02-10 | 2012-06-26 | Thomas Jefferson University | Use of GCC ligands |
EP1781339B1 (de) * | 2004-06-25 | 2013-12-25 | Thomas Jefferson University | Guanylylcyclase C Liganden |
DE102005041131B4 (de) | 2005-08-30 | 2008-01-31 | Phoenix Contact Gmbh & Co. Kg | Übertrager |
US9001515B2 (en) | 2012-04-20 | 2015-04-07 | Cisco Technology, Inc. | Universal pull tab release for modules including fiber optic and cable accessibilities |
US9707467B2 (en) | 2013-10-18 | 2017-07-18 | Under Armour, Inc. | Athletic glove |
US9707565B2 (en) | 2014-04-09 | 2017-07-18 | II Lyman Burdette Lyne | Screen assembly for shredding machine |
-
2001
- 2001-03-27 DE DE60140865T patent/DE60140865D1/de not_active Expired - Lifetime
- 2001-03-27 DE DE60142228T patent/DE60142228D1/de not_active Expired - Lifetime
- 2001-03-27 EP EP18170703.5A patent/EP3388534A1/de not_active Withdrawn
- 2001-03-27 US US09/819,247 patent/US20010036635A1/en not_active Abandoned
- 2001-03-27 EP EP01922785A patent/EP1274861B1/de not_active Expired - Lifetime
- 2001-03-27 US US09/819,248 patent/US20010039016A1/en not_active Abandoned
- 2001-03-27 ES ES01922739T patent/ES2346637T3/es not_active Expired - Lifetime
- 2001-03-27 AT AT01922785T patent/ATE452989T1/de not_active IP Right Cessation
- 2001-03-27 EP EP01922738A patent/EP1268854A4/de not_active Withdrawn
- 2001-03-27 US US09/819,254 patent/US20010029020A1/en not_active Abandoned
- 2001-03-27 AU AU2001249503A patent/AU2001249503A1/en not_active Abandoned
- 2001-03-27 EP EP10163844.3A patent/EP2230320B1/de not_active Expired - Lifetime
- 2001-03-27 WO PCT/US2001/009789 patent/WO2001073131A1/en not_active Application Discontinuation
- 2001-03-27 EP EP01922739A patent/EP1272665B1/de not_active Expired - Lifetime
- 2001-03-27 JP JP2001570846A patent/JP5122713B2/ja not_active Expired - Fee Related
- 2001-03-27 JP JP2001570844A patent/JP2003535580A/ja active Pending
- 2001-03-27 AT AT01922739T patent/ATE469242T1/de not_active IP Right Cessation
- 2001-03-27 US US09/820,215 patent/US20020012931A1/en not_active Abandoned
- 2001-03-27 ES ES10163844.3T patent/ES2548381T3/es not_active Expired - Lifetime
- 2001-03-27 WO PCT/US2001/009790 patent/WO2001073132A1/en active Application Filing
- 2001-03-27 US US09/819,249 patent/US6767704B2/en not_active Expired - Lifetime
- 2001-03-27 AU AU2001249504A patent/AU2001249504A1/en not_active Abandoned
- 2001-03-27 JP JP2001570845A patent/JP2003528628A/ja not_active Ceased
- 2001-03-27 PT PT01922739T patent/PT1272665E/pt unknown
- 2001-03-27 US US09/819,252 patent/US6844153B2/en not_active Expired - Fee Related
- 2001-03-27 CA CA002404428A patent/CA2404428A1/en not_active Abandoned
- 2001-03-27 CA CA002404432A patent/CA2404432A1/en not_active Abandoned
- 2001-03-27 EP EP15174679.9A patent/EP2949762B1/de not_active Expired - Lifetime
- 2001-03-27 AU AU2001249548A patent/AU2001249548A1/en not_active Abandoned
- 2001-03-27 CA CA2404431A patent/CA2404431C/en not_active Expired - Lifetime
- 2001-03-27 WO PCT/US2001/009918 patent/WO2001073133A1/en active Application Filing
-
2003
- 2003-05-02 US US10/428,225 patent/US20040033520A1/en not_active Abandoned
- 2003-06-30 US US10/611,533 patent/US7745114B2/en not_active Expired - Fee Related
-
2004
- 2004-06-14 US US10/866,951 patent/US7854933B2/en not_active Expired - Lifetime
-
2005
- 2005-01-14 US US11/036,875 patent/US7479376B2/en not_active Expired - Fee Related
- 2005-02-16 US US11/058,778 patent/US7485422B2/en not_active Expired - Fee Related
-
2008
- 2008-02-25 US US12/036,875 patent/US20080241064A1/en not_active Abandoned
- 2008-11-17 US US12/272,593 patent/US7785817B2/en not_active Expired - Fee Related
-
2009
- 2009-09-04 US US12/554,572 patent/US20100015167A1/en not_active Abandoned
-
2010
- 2010-06-28 US US12/824,897 patent/US20110250228A1/en not_active Abandoned
- 2010-08-20 US US12/860,835 patent/US20110086064A1/en not_active Abandoned
- 2010-12-06 US US12/961,373 patent/US8067007B2/en not_active Expired - Fee Related
-
2011
- 2011-10-20 US US13/277,612 patent/US8946168B2/en not_active Expired - Fee Related
-
2014
- 2014-10-22 US US14/520,962 patent/US9429576B2/en not_active Expired - Fee Related
-
2016
- 2016-08-26 US US15/249,291 patent/US20170049869A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60142228D1 (de) | Zusammensetzungen und methoden zur identifizierung und zum targeting von krebszellen aus dem verdauungskanal | |
AU2003265556A8 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer | |
WO2003004989A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
WO2003021227A3 (en) | Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors | |
HK1148783A1 (zh) | 用於乳房腺的預後的基因表達標記 | |
ATE223727T1 (de) | Erkennung und modulierung von iaps und naip zur diagnose und behandlung von proliferativen erkrankungen | |
DE69918089D1 (de) | Btk inhibitoren und verfahren zur identifizierung und verwendung | |
EP1567674A4 (de) | Ziel für die therapie einer kognitivenbeeinträchtigung | |
WO2004070062A3 (en) | Compositions and methods for diagnosing and treating cancers | |
WO2003050243A3 (en) | Novel genes encoding colon cancer antigens | |
WO2003000012A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer | |
WO2004106495A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
DE60137264D1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
IL151448A0 (en) | Proteins | |
WO2005007097A3 (en) | Breast cancer genes | |
WO2001042792A3 (en) | Diagnosis of cervical cancer using marker proteins | |
WO2004047757A3 (en) | Diagnosing and treating hematopoietic cancers | |
MXPA05001690A (es) | Estrategia de deteccion para farmacos anticancer. | |
DE69938729D1 (de) | Verfahren zur diagnose von knochenmetastasen aus malignen tumoren | |
ATE332970T1 (de) | Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums | |
DE602007013234D1 (de) | Verfahren und zusammensetzungen zur diagnose und behandlung von krebs | |
DE60140349D1 (de) | Methoden und zusammensetzungen zur diagnose und behandlung von pseudoxanthoma elasticum und ähnlichen zuständen | |
EP1438388A4 (de) | Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen | |
WO2003020294A8 (de) | Markierung der aromatase | |
DE60041561D1 (de) | Zusammensetzungen und Methoden zur Diagnose von Tumoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |